Agenus reports no recurrences in Phase 2 colon cancer drug trial

August 26, 2026 10:05 AM

Agenus Inc. (Nasdaq: AGEN) published updated results from its Phase 2 NEST trial evaluating a combination of botensilimab (BOT) and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found